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Abstract  
Background: Persons with Parkinson disease (PD) experience turning difficulty, often leading to 
freezing of gait and falls. Visual information plays a significant role in locomotion and turning, 
and while the effects of deep brain stimulation (DBS) on oculomotor function have been well 
documented, the effects of DBS on oculomotor function during turning and on turning itself have 
yet to be fully elucidated. Objective: To determine the effects of STN DBS on turning 
performance and related oculomotor performance in PD. Methods: Eleven subjects with PD and 
DBS of the subthalamic nucleus performed a seated voluntary saccade task and standing 180° 
turns in DBS OFF and DBS ON conditions. Oculomotor data were captured using an infrared 
eye tracking system while segment rotations were measured using 3-D motion capture.  Results: 
During the seated saccade task, DBS did not improve saccade amplitude or latency. DBS also 
did not improve gait velocity and stride length during forward walking. During turning, DBS 
improved turn performance (turn duration), reduced the number of saccades performed during 
the turns, and increased the amplitude and velocity of the saccade initiating the turn. DBS 
decreased the intersegmental latencies (eye-head, eye-foot, and head-trunk) but this effect was 
lost for eye-head and eye-foot after controlling for the duration of the first gait cycle. 
Conclusions: DBS significantly improves turn performance and related oculomotor performance.  
These findings add to the growing list of therapeutic benefits offered by DBS.  
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INTRODUCTION  
 
 Turning during gait is common and required during normal ambulation and activities of 
daily living.  Individuals with Parkinson disease (PD), however, experience difficulty turning, 
leading to freezing of gait (FOG), falls, and fear of falling (Bloem et al., 2001; Bloem et al., 
2004; Giladi et al., 1992).  Falls during turns are eight times more likely to result in hip fracture 
than falls during straight line walking, and individuals with PD have a 3.2 fold greater risk of hip 
fracture than age-matched individuals without PD (Melton et al., 2006).  
 Recent studies have attempted to elucidate the cause of turning difficulty in PD in order 
to develop strategies to overcome the issue.  Such studies have noted that persons with PD 
require more steps and take longer to complete a turn than healthy controls (Hong et al., 2009; 
Lohnes and Earhart, 2011; Morris et al., 2001; Stack and Ashburn, 2008)  Additionally, 
individuals with PD show altered timing of segmental rotations during turn initiation, such that 
their turning strategy is more “en bloc” than healthy controls (Crenna et al., 2007; Hong et al., 
2009; Huxham et al., 2008; Visser et al., 2007), although this finding may not be observed in 
early PD stages (Anastasopoulos et al., 2011).   
 It is also clear that visual information plays an integral role in this turning sequence.  In 
healthy controls, the eyes participate in the top-down rotation sequence such that they eyes 
precede the sequential rotations of the head, trunk, and feet (Anastasopoulos et al., 2009).  The 
initial saccade during a turn, in combination with subsequent head movements, provides a shift 
of gaze to a position aligned with the direction of travel.  Gaze shifts precede shifts in center of 
mass (COM) trajectory during turning, and unexpected perturbations of gaze cause delays in 
COM movement to steer the body along the desired trajectory (Vallis, 2001).  In subjects with 
PD, however, the amplitude of the initial saccade is smaller than in healthy controls, a greater 
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number of smaller saccades are performed during the turn, and the timing of the initial s/accade 
relative to the first step is altered. During standing turns, Anastasopoulos et al. (2011) found that 
patients with PD more frequently performed multiple saccades to reach a lateral target and 
expressed altered eye-head-trunk gaze shifts as compared with healthy controls.  Lohnes and 
Earhart (2011) measures saccades during 180 degree turns and found that patients with PD had a 
longer delay between initiation of eye movement and start of the first step of the turn,  and that 
first saccades were smaller and slower than controls. Further, measures of saccade function were 
correlated with turn performance. These oculomotor deficits are consistent with a large body of 
literature supporting voluntary saccade dysfunction in PD.  Prolonged fixation times, 
bradykinesia, and akinesia during rapid alternating gaze shifts have been observed in PD, and 
voluntary saccades are widely described as being smaller and slower in PD (Briand et al., 1999).  
In gaze re-orienting tasks where the eyes rotate in concert with the head to fixate on a lateral 
target, eye-head coordination is found to be abnormal such that both saccades (White, et al., 
1988) and head rotations (Hansen et al., 1990, White et al., 1988) are delayed, hypometric, and 
slow.   
 Few studies have been done to determine the effects of therapeutic interventions on 
turning in PD.  While levodopa therapy is largely effective in improving MDS-UPDRS III scores 
and gait performance (O'Sullivan et al., 1998), the effect on turning dysfunction (turn duration, 
steps to turn, and the timing of body segment rotations) appears to be minimal (Hong and 
Earhart, 2010).  Similarly, the effects of anti-Parkinson medications on saccade function are 
mixed.  While the amplitude of voluntary saccades appears to be resistant to levodopa therapy 
(Crevits et al., 2000; Gibson and Kennard, 1987), levodopa may have a beneficial effect on 
voluntary saccade latencies (Hood et al., 2007; Vermersch et al., 1994), but a negative effect on 
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reflexive saccade latencies (Hood et al., 2007; Michell et al., 2006).  In contrast, the effects of 
subthalamic nucleus (STN) deep brain stimulation (DBS) on oculomotor performance are more 
robust and in line with evidence showing that DBS improves gait velocity and stride length in 
PD (Faist et al., 2001; Ferrarin et al., 2005).  Rivaud-Pechoux et al. (2000) found a positive 
effect of STN DBS on saccade gain during a memory guided saccade task while Sauleau et al. 
(2008)  reported improvements in gain and latency of saccades and gaze during head fixed and 
head free reflexive saccade tasks, respectively, with STN DBS. Finally, Temel et al. (2008; 
2009) found a marked improvement in saccade latency distributions with STN-DBS In summary, 
the effects of DBS on oculomotor function have been well documented and DBS appears to 
provide more robust improvements in oculomotor control .  However, only one study has tested 
the effects of DBS on turning in PD (Naushahi, 2012) and no studies have examined the effects 
of DBS on oculomotor control during turning. Therefore, the purpose of this study was to 
determine the effects of STN DBS on turning performance and related oculomotor performance 
in PD. Based on evidence that DBS improves both gait and oculomotor performance in PD, we 
hypothesized that turning performance would be improved with DBS, including an increase in 
initial saccade amplitude and alterations in the timing of the first saccade relative to turn onset.   
METHODS 
Participants 
 Eleven individuals with idiopathic PD participated in this investigation.  Participants 
were recruited from a database of patients from Washington University School of Medicine’s 
(WUSM) Movement Disorders Center.  All participants met the following inclusion criteria: 
aged 30 years or older, bilateral STN DBS and a minimum of 3 months post implantation 
surgery, currently taking levodopa medication for a minimum of 3 months (levodopa equivalent 
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daily dose, LEDD = 840.8 ± 345.4 mg), normal central (except for PD in the PD group) and 
peripheral neurological function, able to stand independently for at least 30 minutes and walk 
independently without an assistive device, no history of vestibular disease and no evidence or 
history of dementia.   Exclusionary criteria included: any serious medical condition other than 
PD, use of neuroleptic or other dopamine-blocking drug, use of drug that might affect balance 
such as benzodiazepines, evidence of abnormality on brain imaging (previously done for clinical 
evaluations-not part of this research), history or evidence of other neurological deficit, such as 
previous stroke or muscle disease, and history or evidence of orthopedic, muscular, or 
psychological problem that may affect task performance during the study.  Idiopathic PD was 
based on a diagnosis of “definite PD” by a board certified neurologist, as previously described by 
Racette et al. (1999) based upon established criteria (Calne et al., 1992; Hughes et al., 1992).  All 
participants gave written informed consent to perform experimental procedures approved by the 
Human Research Protection Office at WUSM. 
Experimental Procedures 
 All study procedures were performed in the Locomotor Control Laboratory at WUSM.  
Participants were tested in the “OFF” state of their anti-Parkinson medication (i.e. after a 12-hour 
withdrawal of all anti-Parkinson medications). The experimental protocol was performed twice; 
once with DBS stimulators turned on using clinical settings, and once with DBS stimulators 
turned off, with the order of the conditions counterbalanced. Testing procedures began a 
minimum of 45 minutes after DBS settings were changed as it has been shown that 90% of 
changes in motor performance (MDS-UPDRS-III) occur within 45 minutes of DBS being turned 
off, and changes after DBS is turned on occur more quickly, with  90% of changes in motor 
performance occurring in 15-30 minutes (Temperli et. al., 2003). Prior to commencing each 
Running Title: DBS, Medication, and Turning in PD 
round of the experimental protocol, the Movement Disorder Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) Motor Subscale III was administered according to Goetz et al. 
(2008) by a trained rater. The MDS-UPDRS-III is a measure of severity of PD motor symptoms, 
as well as physical disability, and includes measures of rigidity, gait, tremor, hand/arm and leg 
movements (bradykinesia), speech, and facial expressions. The modified Hoehn and Yahr scale 
also was used to evaluate disease severity in PD (Goetz et al., 2004) and the FOG questionnaire 
(FOG-Q) was assessed to categorize freezers and non-freezers (Giladi et al., 2000).    
Saccade Task 
 To evaluate simple voluntary saccade function during an eyes only task, participants 
performed saccades to targets positioned 20° to the left and right of a center target. The task was 
performed in a seated position with the participant’s head positioned in a chin-rest to minimize 
head movement and rotation, and the square targets (2.5 cm X 2.5 cm) were located at eye level 
on a white wall in front of the subject.  Upon hearing an auditory tone, subjects were instructed 
to react as quickly as possible by performing a saccade to one of the lateral targets.  Within each 
block of trials, the order of left and right movements was randomized.  Five trials were 
performed for each target. 
Turning Protocol 
 Following the seated saccade task, participants completed in-place turns of 180° 
amplitude.  Instructions were given to perform the turns in a comfortable and normal fashion.  
No specific auditory or visual cues were provided to cue turn onset or completion other than 
directing subjects to “turn 180 degrees to face the wall behind you.”  Participants were instructed 
to begin the movement anytime after receiving the turn direction instruction of left or right for 
the given trial.  Turns were completed to both the right and left in randomized order. Participants 
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completed a minimum of 5 turns in each direction.  Data quality was visually monitored in real 
time and additional turns were completed as needed to ensure an adequate number of quality 
trials for analysis. 
 Full body kinematic data were captured using an eight camera, passive marker, 3-
dimensional, high–resolution motion capture system (Motion Analysis Corporation, Santa Rosa, 
CA) sampling at 100 Hz in Cortex software (Motion Analysis Corporation, Santa Rosa, CA).  
Thirty-four retro-reflective markers were positioned on the head (top of head, back of head, left 





 thoracic vertebra), pelvis (left and right anterior superior iliac spine, left 
and right posterior superior iliac spine, sacrum), both legs (greater trochanter, anterior thigh, 
lateral femoral condyle, tibial tuberosity, front of shank, lateral malleolus) and both feet 
(calcaneus, navicular, distal 2
nd
 metatarsal). Ocuolmotor data were captured using a head-
mounted infrared binocular eye tracking system (Applied Sciences Laboratory, Bedford, MA) 
and electrooculography (EOG).  Oculomotor data were captured synchronously at 1000Hz on the 
same PC workstation with kinematic data in Cortex software.   
Walking Task 
 To confirm the clinical benefit of DBS, subjects performed 3 trials of forward walking at 
a comfortable, self-selected pace across a 5 m instrumented, computerized GAITRite walkway 
(CIR Systems, Inc., Havertown, PA). Gait velocity and stride length were used as measures of 
gait function.  
Data Processing 
 Individual kinematic marker data and analog data were filtered using 4th order low-pass 
Butterworth filters.  Marker data were filtered in Cortex with a cut-off frequency of 6 Hz while 
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analog data were filtered in MotionMonitor (Innsport, Chicago, IL) with a cut-off frequency of 
20 Hz.  Global and segment coordinate systems were defined in MotionMonitor with the positive 
X-axis pointing anteriorly, positive Y-axis pointing to the left, and positive Z-axis pointing 
upward vertically.  For the turning task, rotations of the head, trunk, pelvis, and feet about global 
Z were extracted using a Z-X-Y Euler sequence.  Subsequently, kinematic angle data and filtered 
analog data were exported for further processing in custom written MATLAB software (The 
Mathworks, Inc., Natick, MA).  
 For the turning task, we characterized the timing of the rotation sequence by identifying 
the time of onset of each segment yaw rotation (relative to the global coordinate system).  This 
was determined by identifying the first frame at which the yaw rotation reached five degrees 
above baseline.  Similar criteria were used to identify turn offset, defined as the frame at which 
the yaw rotation came within five degrees of maximal, final position. Eye tracker and EOG data 
were used to identify and measure saccades occurring just prior to and during turn performance.  
Saccades were identified visually and later confirmed to be true saccades if the maximum 
velocity of the eye movement exceeded 30 degrees/sec (Chan et al., 2005; Versino et al., 2005).  
Onsets and offsets of the first saccade associated with each turn were identified visually. Using 
these time points, saccade amplitude, peak velocity, and timing of the first saccade relative to 
head and foot rotations were calculated.  Our primary variables of interest for the turning task 
were the amplitude and velocity of the saccade initiating the turn, the total number of saccades 
performed during the turn, turn duration, and the timing of the first saccade relative to the onset 
of the first step. Secondary variables of interest included the timing of the turning sequence, i.e. 
the timing of each body segment (head, trunk, pelvis) relative to the first step of the turn and the 
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relationship between peak saccade velocity and amplitude, or main-sequence-slope, calculated as 
saccade peak velocity/ saccade peak amplitude.   
 For the seated task, the first saccade following the auditory cue was measured in a similar 
manner.  Variables of interest were the latency of saccade onset with respect to the auditory cue 
and saccade amplitude. 
 Individual trials were excluded from analysis if eye position or body segment rotations 
about the global Z-axis (during the turn task) were not static for at least 1000ms prior to turn 
onset.  Trials were also excluded if artifacts in oculomotor data due to blinks, prolonged closure 
of eyelids, or other factors precluded measurement of the initial saccade.  Remaining trials were 
averaged to obtain a single data point for each combination of medication and DBS state within 
each subject.  For the turning and seated tasks, left and right trials were combined for analysis as 
performance did not differ between leftward and rightward trials. 
Data Analysis 
 Prior to performing statistical tests, all variables were tested for normality and each 
variable was examined visually for outliers, for which none were identified.  To compare 
between DBS-OFF and DBS-ON, variables that were normally distributed were tested using 
parametric paired t-tests, while variables found to violate the normality assumption were tested 
using the Related-Samples Wilcoxon Signed Rank Test.  Pearson’s correlations coefficient was 
employed to examine correlations between clinical measures and turn performance data.  All 
statistical tests were two tailed with criterion for statistical significance set at p<0.05.  
RESULTS  
 Demographic data are displayed in Table 1; performance data are displayed in Tables 2 
and 3.  MDS-UPDRS III scores improved significantly with DBS (t=4.04, p=0.002) while gait 
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velocity and stride length did not (t=1.59, p=0.143; t=1.37, p=0.202, respectively).  DBS 
significantly decreased turn duration (t=2.59, p=0.027) and the number of saccades performed 
during turns (t=5.133, p<0.001) and increased the amplitude and velocity of the first saccade 
performed during the turn (t=4.96, p=0.001; t=3.82, p=0.003, respectively).  The main-sequence-
slope was also decreased with DBS (DBS OFF=17.78 ± 8.3, DBS ON = 13.02 ± 5.6; t=3.72, 
p=0.004). 
 In correlating clinical measures with kinematic measures, baseline MDS-UPDRS-III 
scores (DBS-OFF) correlated with the percentage of improvement in saccade amplitude 
(r=0.759, p=0.007).  Baseline MDS-UPDRS-III scores were not significantly correlated with 
improvements in turn duration (r=-0.366, p=0.268), saccade velocity (r=0.260, p=0.440), or the 
number of saccade performed during the turn (r=-0.584, p=0.059). Baseline postural instability 
and gait (PIGD, items 3.15 - 3.19 from MDS-UPDRS-III) correlated with improvements in 
saccade amplitude (r=0.623, p=0.40), velocity (r=0.631, p=0.37), and number (r=-0.731, 
p=0.011), while the baseline PIGD correlation with improvements in turn duration approximated 
significance (r=0.585, p=0.059). 
 In characterizing the timing of the rotation sequence, DBS decreased the eye-head 
(t=2.18, p=0.055), eye-foot (t=4.21, p=0.002), and head-trunk (t=2.40, p=0.037) latencies.  When 
dividing the latencies by the duration of the first gait cycle to obtain normalized latencies in 
order to control for turning speed, each of the above effects of DBS were removed (t=0.78, 
p=0.455; t=0.612, p=0.554; t=1.54, p=0.154, respectively).  Finally, during the seated tasks, 
there were no significant effects of DBS (t=0.059, p=0.954; t=1.45, p=.182) in regards to saccade 
latency or amplitude, respectively.   
DISCUSSION 
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 The purpose of this study was to determine the effects of  DBS on measures of turning 
performance and related oculomotor performance in PD.  In summary, DBS had a profound 
effect on turning duration and the number of saccades performed during the turn.  DBS also 
increased the amplitude, velocity, and main-sequence-slope of the first saccade performed during 
the turn. Finally, the intersegmental latencies between the eyes, head, trunk, and feet were 
decreased by DBS, however this effect was eliminated when we controlled for turning speed.   
 To the best of our knowledge, this is the first study to address the therapeutic effects of 
DBS on turning in PD as well as the first to measure the effects of DBS on oculomotor function 
during a functionally relevant task.  Our findings are consistent with previous research that 
shows an improvement in motor symptoms (MDS-UPDRS III) with DBS.  DBS was also 
effective in increasing gait velocity by approximately 13% and stride length by approximately 
10% in our study, although these differences did not reach statistical significance. Our findings 
of improved turning duration and concomitant improvements in oculomotor performance during 
turns are novel yet anticipated based on the efficacy of DBS in improving saccade function and 
gait in previous studies.  Previous work in our lab (Lohnes and Earhart, 2011) showed that 
persons with PD turn slower and with more steps than healthy, age-matched controls, and that 
turn performance is correlated with oculomotor function such that individuals who perform later, 
larger, faster, and fewer saccades turn better.  Similarly, data herein suggest that improved 
oculomotor performance associated with DBS is correlated with improved turn performance.  
Neither of these studies, however, address a cause-and-effect relationship between oculomotor 
and turn performance.  Since the oculomotor system initiates the turning sequence, we 
hypothesize that saccades occurring before and early in the turn sequence may affect subsequent 
turning kinematics, but it is also plausible that improvements in oculomotor function (as 
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measured herein) are driven by improved turn performance. For example, a decrease in the 
number of saccades performed during the turn may be an effect of shortened turn duration and 
increased turn speed. Beyond the role of the oculomotor system, other factors are also likely to 
contribute to the improved turn performance noted with DBS.  DBS improved overall MDS-
UPDRS-III scores as well as bradykinesia, rigidity, and PIGD, measures that are all independent 
from saccade function but could affect turn performance.  DBS also produced a shortening of 
intersegmental latencies (eye-head, eye-foot, head-trunk). Again, while DBS-related 
improvements in saccade function could have contributed to this, the decreased intersegmental 
latencies are most likely due to the increased speed with which subjects were able to complete 
the turns during DBS stimulation, hence shortening all aspects of the turn sequence.  This 
hypothesis is supported by the fact that intersegmental latencies were similar when we controlled 
for the duration of the first gait cycle. 
 Subjects in this study displayed a top-down rotation sequence in regards to the timing of 
rotation onset of the various segments (eye-head, head-trunk, trunk-foot).  This is in contrast to 
Hong & Earhart (2010) and  Hong et al. (2009) which reported en bloc timing in a group of non-
DBS PD patients, but in line with Anastasopoulos et al.(2011) who observed a top-down rotation 
sequence in a sample of mild PD patients.  It is possible that the turning sequence used herein is 
still more “en bloc” than the pattern utilized by healthy controls, and perhaps falls somewhere 
between that observed by Hong et al. and Anastasopoulos.   
 While DBS improved walking and turning performance, it did not improve saccade 
performance during the seated saccade task, which is contrary to previous research showing 
beneficial effects of DBS on saccade performance.  There were, however, some methodological 
differences between ours and previous studies.  Previous studies examined the effects of DBS on 
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both voluntary (memory guided saccades, anti-saccades) and reflexive saccades using protocols 
where the saccade was cued visually (either the appearance of a lateral target or the 
disappearance of the central target).  In our study, we used an auditory cue to initiate the saccade.  
Furthermore, our targets were static in that they remained in view for the duration of the test.  In 
contrast to memory-guided or anti-saccade paradigms where the subjects perform saccades to a 
target-less location, our subjects made saccades toward a static visual target which may have 
served as an external cue that facilitated performance.      
Limitations 
 There are a few limitations related to this study.  First, we did not consider specific 
electrode placement within the STN when selecting participants, resulting in some likely 
heterogeneity among subjects in regards to stimulation localization within the STN.  While 
saccade-related neurons are clustered in the ventral STN (Fawcett et al., 2005; Matsumura et al., 
1992), PD motor symptoms such as gait and balance appear to respond similarly to dorsal and 
ventral STN DBS (McNeely et al., 2011).  As such, functional tasks that significantly involve the 
oculomotor system (e.g. turning) may be best ameliorated by DBS in the ventral STN. Selecting 
sub-groups of patients based on electrode placement (ie: dorsal vs. ventral STN) may offer 
further understanding of the effect of STN DBS on oculomotor function during turning, but 
cognitive function must be considered in such studies as response inhibition has been shown to 
decrease with ventral STN DBS (Hershey et al., 2010).  Second, during the seated saccade task, 
we used a novel paradigm with static targets and an auditory cue. This may explain the lack of 
effect of DBS on saccade amplitude and latency.  Finally, our relatively small sample size may 
have contributed to the lack of statistical significance observed in gait parameters.  
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Conclusions/Implications 
 In conclusion, STN DBS is largely effective in improving both straight walking and 
turning performance in PD, including increases in saccade amplitude and a decreased number of 
saccades required to complete the turn.  These results add to the growing number of known 
benefits offered by DBS, and add to the functional applicability of previous research that has 
found beneficial effects of DBS on saccades and gaze during seated tasks.  Future work may aim 
to define optimal DBS electrode placement for patients whose primary motor complications 
include freezing during turning, or a history of falls during turns.   
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FIGURES 
 
Figure 1. Representative data from individual turn trials showing eye-in-head, head-over-
ground, and foot-over-ground rotations about the z (vertical) axis. Top = DBS OFF, Bottom = 
DBS ON. All turns are to the right and are initiated with the right foot.  DBS improves turn 
duration and reduce the number of saccades required to complete the turn. 
 
 
Running Title: DBS, Medication, and Turning in PD 
 
Figure 2.  Effects of DBS on oculomotor performance during turns. *Significant difference 
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Table 2. GAITRite and Seated Saccade Task Data 
____________________________________________________________  
      DBS OFF     DBS ON   
GAITRite Data 
Gait Velocity (cm/s)    94.9 ± 30.1   106.8 ± 20.5   
Stride Length (cm)  103.8 ± 25.2   113.4 ± 17.9   
  
Seated Saccade Task 
Saccade Latency (ms)  335.8 ± 98.0   335.0 ± 104.0  
Saccade Amplitude (°)   15.0 ± 2.1     16.0 ± 1.3   
Values are means ± standard deviations. 
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Table 3. Kinematic Performance Data 
__________________________________________________________________   
      DBS OFF   DBS ON   
Eye-Head Latency (ms)    320.3 ± 275.6           * 168.9 ± 133.6   
   
Head-Trunk Latency (ms)      71.5 ± 115.1           *   11.8 ± 48.2   
 
Eye-Foot Latency (ms)     667.2 ± 438.1           *  334.5 ± 289.8    
 
N. Eye-Head Latency     306.8 ± 179.4    247.4 ± 277.4   
  
N. Eye-Foot Latency (% First Gait cycle)     48.8 ± 33.5      59.9 ± 76.7   
   
N. Head-Trunk Latency (% First Gait cycle)      7.5 ± 12.1        2.7 ± 6.6     
 
N. Head-Foot Latency (% First Gait cycle)    18.2 ± 29.2      35.1 ± 49.9   
Values are means ± standard deviations. 
* Significant difference (p<0.05) 
 
 
